TIDMAGY

RNS Number : 1108T

Allergy Therapeutics PLC

30 December 2016

30 December 2016

Allergy Therapeutics plc

("Allergy Therapeutics" or the 'Company")

Grant of Awards under Long Term Incentive Plan

Allergy Therapeutics (AIM:AGY), the fully integrated pharmaceutical company specialising in allergy vaccines, announces that, pursuant to the Company's Long Term Incentive Plan ("LTIP") the following conditional awards of shares of 0.1 pence each were made to Executive Directors at nominal cost of 0.1 pence each on 30 December 2016.

 
 Executive Director    Number of Conditional   Total conditional 
                        shares awarded          shares held under 
                                                LTIPs 
--------------------  ----------------------  ------------------- 
 Manuel Llobet         1,690,000               3,380,000 
--------------------  ----------------------  ------------------- 
 Nick Wykeman          422,500                 422,500 
--------------------  ----------------------  -------------------

The issuance and distribution of ordinary shares of 0.1 pence each under the LTIP is conditional on the satisfaction of performance conditions which include an earnings growth test over a three year testing period to 30 June 2019 and share price growth over the 3 year plan cycle.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1     Details of the person discharging managerial 
        responsibilities / person closely associated 
----  ------------------------------------------------------------ 
 a)    Name                 Manuel Llobet 
                             Nicolas Wykeman 
----  -------------------  --------------------------------------- 
 2     Reason for the notification 
        Grant of conditional awards of 0.1 pence each 
----  ------------------------------------------------------------ 
 a)    Position/status      Manual Llobet - Chief Executive Office 
                             Nicolas Wykeman - Finance Director 
----  -------------------  --------------------------------------- 
 b)    Initial              Initial notification 
        notification 
        /Amendment 
----  -------------------  --------------------------------------- 
 3     Details of the issuer, emission allowance market 
        participant, auction platform, auctioneer or 
        auction monitor 
----  ------------------------------------------------------------ 
 a)    Name                 ALLERGY THERAPEUTICS PLC 
----  -------------------  --------------------------------------- 
 b)    LEI 
----  -------------------  --------------------------------------- 
 4     Details of the transaction(s): section to be 
        repeated for (i) each type of instrument; (ii) 
        each type of transaction; (iii) each date; 
        and (iv) each place where transactions have 
        been conducted 
----  ------------------------------------------------------------ 
 a)    Description          Conditional award of shares under 
        of the financial     the Company's Long Term Incentive 
        instrument,          Plan 
        type of 
        instrument 
 
        Identification 
        code 
----  -------------------  --------------------------------------- 
 b)    Nature of 
        the transaction 
----  -------------------  --------------------------------------- 
       Price(s) 
 c)     and volume(s)         1,690,000 
----  -------------------  --------------------------------------- 
 d)    Aggregated 
        information 
        - Aggregated 
        volume 
        - Price 
----  -------------------  --------------------------------------- 
 e)    Date of              30 December 2016 
        the transaction 
----  -------------------  --------------------------------------- 
 f)    Place of             Outside a trading venue 
        the transaction 
----  -------------------  ---------------------------------------

Name of authorised official of issuer responsible for making notification:

 
 Allergy Therapeutics 
  +44 (0) 1903 845 820 
 Manuel Llobet, Chief Executive Officer 
 Nick Wykeman, Finance Director 
 
 
 Panmure Gordon 
  +44 (0) 20 7886 2500 
  Freddy Crossley / Duncan Monteith, Corporate 
  Finance 
  Tom Salvesen, Corporate Broking 
 Consilium Strategic Communications 
  +44 20 3709 5700 
  Mary-Jane Elliott / Ivar Milligan 
  allergytherapeutics@consilium-comms.com

Note to editors:

About Allergy Therapeutics

Allergy Therapeutics is an international specialty pharmaceutical company focussed on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that cure disease. The Company sells proprietary products and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with MHRA-approved manufacturing facilities. The Company employs c.420 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHZBLFXQLFLFBD

(END) Dow Jones Newswires

December 30, 2016 09:31 ET (14:31 GMT)

Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Allergy Therapeutics Charts.
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Allergy Therapeutics Charts.